 |
 |
 |
|
What to expect from this product:
- Aids weight loss
- Increases lean muscle
- Accelerates fat loss in those that exercise
- Reduces the risk of hardening of the arteries (atherosclerosis)
- Builds healthier bone and cartilage
- Reduces inflammation
- Modulates the immune system
- Controls blood sugar
Suggested Usage: 1-2 softgels daily before meals. Keep out of reach of children.
Each Softgel Contains:
TonalinTM Proprietary Blend 1000 mg
Conjugated Linoleic Acid (CLA) 740 mg
Encapsulated in a softgel capsule (gelatin, glycerin, purified water, caramel).
CLA is considered to be necessary for both cell growth and as a building block of cell
membranes. It naturally occurs in dairy foods and grass-fed beef and lamb. The intestinal
bacteria of these animals converts omega 6 linoleic acid into CLA. Humans cannot convert
linoleic acid into CLA so we are completely reliant on the foods we eat or supplementation
to acquire the necessary CLA. Unfortunately, the CLA content of dairy and meat products
has declined due to increased antibiotic use in cattle, which destroys the intestinal bacteria,
and changes in the cattle's food supply from grass to grain.
Several hundred published research studies support CLA's ability to exert positive effects on
fat loss, prevent and control type 2 diabetes, protect against heart disease, reduce the risk of
atherosclerosis, build healthier bones and modulate the immune response. It may also inhibit
the growth of certain cancers of the breast, prostate and colon.
CLA Melts Fat
CLA is included as part of the BodySense Natural Diet Program due to its profound effect
on fat loss and improving lean muscle mass.
Animal research in 1951 paved the way for further groundbreaking research on CLA and fat loss
in humans. The first human clinical trial using CLA was conducted in 1997 in Norway and
published in The Journal of Nutrition in 2000. This 90 day double-blind, randomized, placebocontrolled
study found a reduction in body fat with an average weight loss of seven pounds of
fat and an increase in lean body mass with a 20% decrease in body fat. CLA also stops fat from
coming back once participants stop dieting. According to research published in 2001 in The
Journal of International Medical Research those who take CLA and exercise increase fat loss and
conversion of fat to lean muscle in a shorter period of time and with lower doses of CLA.
CLA and Bone Biology
Research published in The Journal of the American College of Nutrition in 2000 found that
CLA had an anti-inflammatory effect by moderating COX-2 enzymes and reducing pain and
inflammation. Inflammation promotes cartilage breakdown and osteoporosis. Controlling
inflammation is essential to ensuring adequate calcium levels in bone, thereby maintaining
strong bone and cartilage. Animal studies have shown CLA to improve bone formation and
reduce cartilage damage. Scientists believe CLA may help reduce pain and inflammation in
those with arthritis and rheumatoid arthritis as well.
CLA improves insulin sensitivity
Several studies have shown CLA is able to prevent and control adult onset diabetes by sensitizing
insulin. Researchers at Purdue University in Indiana reported a dramatic improvement in serum
insulin response in patients taking 6 grams of CLA daily. Over 64% of patients in this eight week
trial had an improvement in leptin levels - a hormone that regulates both insulin and weight gain.
CLA Research:
Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans.
Gaullier
JM, Halse
J, Hoye
K, Kristiansen
K, Fagertun
H, Vik
H, Gudmundsen
O.
Scandinavian Clinical Research AS, NO-2027 Kjeller, Norway. j-m@scr.no
After 12 months in a randomized, double-blind, placebo-controlled
trial of conjugated linoleic acid (CLA) supplementation (2 groups received CLA
as part of a triglyceride or as the free fatty acid, and 1 group received olive
oil as placebo), 134 of the 157 participants who concluded the study were
included in an open study for another 12 months. The goals of the extension study
were to evaluate the safety [with clinical chemistry analyses and reported
adverse events (AEs)] and assess the effects of CLA on body composition [body
fat mass (BFM), lean body mass (LBM), bone mineral mass (BMM)], body weight, and
BMI. All subjects were supplemented with 3.4g CLA/d in the triglyceride form.
Circulating lipoprotein(a) and thrombocytes increased in all groups. There was
no change in fasting blood glucose. Aspartate amino transferase, but not alanine
amino transferase, increased significantly. Plasma total cholesterol and LDL
cholesterol were reduced, whereas HDL cholesterol and triglycerides were
unchanged. The AE rate decreased compared with the first 12 months of the study.
Body weight and BFM were reduced in the subjects administered the placebo during
the initial 12 month study (-1.6 +/- 3.2 and -1.7 +/- 2.8 kg, respectively). No fat
or body weight changes occurred in the 2 groups given CLA during the initial 12
months. LBM and BMM were not affected in any of the groups. Changes in body
composition were not related to diet and/or training. In conclusion, this study
shows that CLA supplementation for 24 mo in healthy, overweight adults was well
tolerated. It confirms also that CLA decreases BFM in overweight humans, and may
help maintain initial reductions in BFM and weight in the long term.
Additional Abstracts and Studies:
|
|
|
|
|
|
|
|
|
